Olmesartan PCD Pharma Franchise Company
Cafoli Lifecare is a trusted Olmesartan PCD pharma franchise company in India, offering 16 Olmesartan formulations in tablet form, including fixed-dose antihypertensive combinations. Every batch is manufactured at WHO-GMP certified, DCGI-approved facilities, and franchise partners receive exclusive district-wise monopoly rights on the full cardiac range.
What is Olmesartan?
Olmesartan is an angiotensin II receptor blocker (ARB). It selectively blocks the binding of angiotensin II to the AT1 receptor in vascular smooth muscle and the adrenal gland, preventing angiotensin-mediated vasoconstriction and aldosterone release. The result is arterial vasodilation, reduced peripheral vascular resistance and a sustained fall in blood pressure, without the bradykinin-mediated dry cough associated with ACE inhibitors. It is indicated for the treatment of hypertension, alone or in combination with other antihypertensive agents. Compound data is available on PubChem.
Available Olmesartan Formulations
The Cafoli Lifecare Olmesartan range comprises 16 formulations, available in the following dosage form:
Brand names, compositions, pack sizes and net rates are shared with registered franchise enquiries. Contact our team for the current Olmesartan price list.
Therapeutic Applications of Olmesartan
Prescribed under medical supervision for:
- Essential hypertension, as monotherapy or in combination
- Hypertension in patients intolerant of ACE inhibitors due to cough
- Blood pressure control in patients with type 2 diabetes and chronic kidney disease, where renin-angiotensin blockade is indicated
- Combination therapy with diuretics or calcium channel blockers in resistant hypertension
Prescriber specialties: cardiologists, consulting physicians, nephrologists and diabetologists. Olmesartan is a prescription-only medicine and is contraindicated in pregnancy.
Why Olmesartan is a High-Potential Molecule for Distributors
Hypertension is the largest chronic therapy market in India and one of the most under-treated, so the patient pool keeps expanding rather than saturating. Within that market, ARBs are the fastest-growing class, steadily taking share from ACE inhibitors for a simple reason: patients tolerate them, and patients who tolerate a drug stay on it. For a franchise partner, adherence is the whole business model — a hypertensive patient retained on therapy is a repeat prescription every single month, for years, with almost no acquisition cost after the first. Olmesartan's 16 formulations, including dual and triple fixed-dose combinations, also mean the distributor can follow the patient up the treatment ladder as the physician escalates therapy, rather than losing the sale to a competitor's combination product. Cardiology and diabetology clinics are concentrated and easy to cover, which keeps field costs low relative to the revenue generated.
Why Choose Cafoli Lifecare
- Monopoly rights — exclusive district-wise marketing rights for the Olmesartan range
- WHO-GMP certified manufacturing and DCGI-approved products
- Promotional inputs — visual aids, MR bags, prescription pads, samples and reminder cards
- 1000+ franchise partners across India with an on-time dispatch record
- Transparent net rates and dedicated franchise support
References
- PubChem — Olmesartan compound record
- PubMed — Olmesartan in hypertension
- WHO Model List of Essential Medicines
Our formulations of Olmesartan find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: